Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11111509 | PMC |
| http://dx.doi.org/10.1007/s11523-024-01053-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment.
Drugs Real World Outcomes
December 2024
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate, 028-3694, Japan.
Article Synopsis
- Durvalumab plus tremelimumab (Durva/Treme) is a newly approved treatment for unresectable hepatocellular carcinoma (u-HCC) in Japan, and researchers assessed its real-world outcomes.
- A study evaluated 22 patients at Iwate Medical University who received Durva/Treme, comparing outcomes between those treated as first-line vs. later-line therapy.
- Results showed no significant differences in progression-free survival, objective response rate, disease control rate, or adverse event incidence between the two groups, suggesting Durva/Treme is effective and safe for u-HCC patients regardless of treatment line.
Correction to: Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
Target Oncol
May 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy.
Arch Pathol Lab Med
November 2020
and Weill Cornell Pathology, New York, New York (Borczuk).
Context.—: Cardiac complications of immune checkpoint inhibitor therapy are rare, but reports of myocarditis are increasing. The findings have been described in case reports as lymphocytic myocarditis, but its histopathology is underreported.
View Article and Find Full Text PDFOverview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice.
Cancers (Basel)
October 2019
HCC Special Interest Group, Associazione Italiana per lo Studio del Fegato (AISF), 00199 Roma, Italy.
Despite progress in our understanding of the biology of hepatocellular carcinoma (HCC), this tumour remains difficult-to-cure for several reasons, starting from the particular disease environment where it arises-advanced chronic liver disease-to its heterogeneous clinical and biological behaviour. The advent, and good results, of immunotherapy for cancer called for the evaluation of its potential application also in HCC, where there is evidence of intra-hepatic immune response activation. Several studies advanced our knowledge of immune checkpoints expression in HCC, thus suggesting that immune checkpoint blockade may have a strong rationale even in the treatment of HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!